<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409770</url>
  </required_header>
  <id_info>
    <org_study_id>241031</org_study_id>
    <secondary_id>37318</secondary_id>
    <nct_id>NCT03409770</nct_id>
  </id_info>
  <brief_title>Optimising the Duration of Cooling in Mild Encephalopathy</brief_title>
  <acronym>COMET</acronym>
  <official_title>Optimising the Duration of Cooling Therapy in Mild Neonatal Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thayyil, Sudhin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thayyil, Sudhin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II randomised control trial of whole body cooling in mild neonatal encephalopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although therapeutic hypothermia for 72 hours reduces brain injury and improves long term
      neurodevelopmental outcomes after moderate or severe neonatal encephalopathy, the benefits
      and optimal duration of cooling therapy in mild encephalopathy is not known. Adverse
      neurodevelopmental outcomes at 2 years occur in 16% of babies with un-treated mild neonatal
      encephalopathy. In the phase I of the COMET trial, we have shown that it is feasible to
      identify and randomise babies with mild encephalopathy, and to obtain the primary outcome
      (proton MR spectroscopy levels of Thalamic N-acetyl Aspartate) accurately. The phase II of
      the COMET trial will examine the benefits and optimal duration of cooling therapy in babies
      with mild encephalopathy.

      Research questions

        1. Does whole body cooling initiated within 6 hours of birth and continued for 72 hours
           increase thalamic MR spectroscopy N-acetyl aspartate levels in babies with mild
           encephalopathy, when compared with those who are not cooled? (Cohort 1)

        2. In babies with mild encephalopathy undergoing cooling therapy as clinical care, does
           rewarming at 48 hours as opposed to 72 hours result in similar thalamic N-acetyl
           aspartate levels? (Cohort 2)

      Study Population Cohort 1: A total of 60 babies with mild encephalopathy (&gt;36 weeks; &gt;2Kg)
      aged less than 6 hours will be recruited from several tertiary neonatal units in the UK,
      Europe, USA and Canada, over a 2 year period. The babies will be randomised to usual care (no
      cooling) or cooling therapy (core temperature 33 to 34 C) for 72 hours within six hours of
      birth. MR imaging and spectroscopy will be performed between 4 to 14 days after birth.

      Cohort 2: A total of 80 babies will mild encephalopathy (&gt;36 weeks; &gt;2Kg) aged 24 to 48 hours
      and undergoing cooling therapy as a part of standard clinical care will be recruited from
      several UK cooling centres, over a 2 year period. The babies will be randomised to rewarming
      after 48 hours or 72 hours of cooling therapy. MR imaging and spectroscopy will be performed
      between 4 to 14 days after birth. The babies recruited to cohort 1 will not be eligible for
      recruitment to cohort 2.

      Primary outcome (both cohorts)

      â€¢ Proton MR spectroscopy Thalamic N-acetyl aspartate levels between 4 to 14 days of age.

      Benefits of the trial These data will inform the national and international guidelines on
      management of babies with mild neonatal encephalopathy. If a shorter duration of cooling is
      as good or better than 3 days of cooling, this will reduce the intensive care stays, opioid
      use and separation from parents.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Therapeutic hypothermia (33 to 34 C) for 2 different durations (48, or 72 h) and usual care (normothermia)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>MR spectroscopy analysis will be masked to the allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Thalamic N-acetyl aspartate level</measure>
    <time_frame>4 to 14 days after birth</time_frame>
    <description>Feasibility of obtaining Proton MR spectroscopy thalamic N-acetyl aspartate level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain injury on conventional MR imaging</measure>
    <time_frame>4 to 14 days after birth</time_frame>
    <description>Cortical, white matter or deep nuclei injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>Upto 30 days after birth</time_frame>
    <description>Duration of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Neonatal Encephalopathy</condition>
  <condition>Hypothermia Neonatal</condition>
  <condition>Magnetic Resonance Spectroscopy</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care (normothermia) arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic hypothermia - 48 h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole body cooling (33 to 34 C) for 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic hypothermia - 72 h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole body cooling (33 to 34 C) for 72 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic hypothermia</intervention_name>
    <description>Whole body cooling using a servo controlled device</description>
    <arm_group_label>Therapeutic hypothermia - 48 h</arm_group_label>
    <arm_group_label>Therapeutic hypothermia - 72 h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

        All of the following three criteria should be met:

          1. Age less than six hours. AND

          2. Evidence of acute perinatal asphyxia

               1. Metabolic acidosis (pH &lt;7.0 and/or BE &gt;-16) in cord gas or a blood gas within one
                  of birth.

                  OR

               2. If the pH or BE is borderline (pH&lt;7.15 to 7.0) and/or BE &gt;-10 to -16) in cord
                  and/or blood gas within 1h of birth additional evidence of perinatal asphyxia is
                  required, which includes either an acute obstetric event (e.g. cord prolapse,
                  abruption, shoulder dystocia) OR Need for continued resuscitation or ventilation
                  at 10 minutes and/or a 10 min Apgar score &lt;6

          3. Evidence of mild NE (at-least two abnormalities) on an NICHD neurological examination
             performed between 1 and 6h of birth.

        EXCLUSION CRITERIA

        The following group of babies will be excluded prior to randomisation

          1. Babies without encephalopathy

          2. Babies with moderate or severe encephalopathy who meet the current NICE/AAP guidelines
             for cooling therapy.

          3. Babies with seizures (clinical and/or aEEG/EEG)

          4. Babies with moderate or severe abnormalities on aEEG voltage criteria.

          5. Babies with life threatening congenital malformations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudhin Thayyil, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Morales</last_name>
    <phone>0044203 313 2473</phone>
    <email>m.moreno-morales@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Morales</last_name>
    <email>m.moreno-morales@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Michigan Center</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seetha Shankaran, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sanjay Chawla, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Birmingham Womens Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manobi Boorah, FRCPCH</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medway NHS Foundation Trust</name>
      <address>
        <city>Gillingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Aung Soe, FRCPCH</last_name>
      <email>aung.soe@medway.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Russel Pryce, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Liverpool Womens Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Yajamanym Yajamanym, FRCPCH</last_name>
      <phone>07809119027</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Homerton University Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narendra Aldangady</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudhin Thayyil, PhD</last_name>
      <phone>07912888700</phone>
      <email>s.thayyil@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Pete Lally, PhD</last_name>
      <email>p.lally@imperial.ac.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Newcastle Upon Tyne NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Sundeep Harigopal</last_name>
      <email>sundeep.harigopal@nuth.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Prempunpong C, Chalak LF, Garfinkle J, Shah B, Kalra V, Rollins N, Boyle R, Nguyen KA, Mir I, Pappas A, Montaldo P, Thayyil S, SÃ¡nchez PJ, Shankaran S, Laptook AR, Sant'Anna G. Prospective research on infants with mild encephalopathy: the PRIME study. J Perinatol. 2018 Jan;38(1):80-85. doi: 10.1038/jp.2017.164. Epub 2017 Nov 2.</citation>
    <PMID>29095433</PMID>
  </reference>
  <reference>
    <citation>Oliveira V, Singhvi DP, Montaldo P, Lally PJ, Mendoza J, Manerkar S, Shankaran S, Thayyil S. Therapeutic hypothermia in mild neonatal encephalopathy: a national survey of practice in the UK. Arch Dis Child Fetal Neonatal Ed. 2018 Jul;103(4):F388-F390. doi: 10.1136/archdischild-2017-313320. Epub 2017 Sep 23.</citation>
    <PMID>28942433</PMID>
  </reference>
  <reference>
    <citation>Lally PJ, Montaldo P, Oliveira V, Swamy RS, Soe A, Shankaran S, Thayyil S. Residual brain injury after early discontinuation of cooling therapy in mild neonatal encephalopathy. Arch Dis Child Fetal Neonatal Ed. 2018 Jul;103(4):F383-F387. doi: 10.1136/archdischild-2017-313321. Epub 2017 Sep 21.</citation>
    <PMID>28935718</PMID>
  </reference>
  <reference>
    <citation>Lally PJ, Pauliah S, Montaldo P, Chaban B, Oliveira V, Bainbridge A, Soe A, Pattnayak S, Clarke P, Satodia P, Harigopal S, Abernethy LJ, Turner MA, Huertas-Ceballos A, Shankaran S, Thayyil S. Magnetic Resonance Biomarkers in Neonatal Encephalopathy (MARBLE): a prospective multicountry study. BMJ Open. 2015 Sep 30;5(9):e008912. doi: 10.1136/bmjopen-2015-008912.</citation>
    <PMID>26423856</PMID>
  </reference>
  <reference>
    <citation>Robertson NJ, Thayyil S, Cady EB, Raivich G. Magnetic resonance spectroscopy biomarkers in term perinatal asphyxial encephalopathy: from neuropathological correlates to future clinical applications. Curr Pediatr Rev. 2014;10(1):37-47. Review.</citation>
    <PMID>25055862</PMID>
  </reference>
  <reference>
    <citation>Lally PJ, Price DL, Pauliah SS, Bainbridge A, Kurien J, Sivasamy N, Cowan FM, Balraj G, Ayer M, Satheesan K, Ceebi S, Wade A, Swamy R, Padinjattel S, Hutchon B, Vijayakumar M, Nair M, Padinharath K, Zhang H, Cady EB, Shankaran S, Thayyil S. Neonatal encephalopathic cerebral injury in South India assessed by perinatal magnetic resonance biomarkers and early childhood neurodevelopmental outcome. PLoS One. 2014 Feb 5;9(2):e87874. doi: 10.1371/journal.pone.0087874. eCollection 2014. Erratum in: PLoS One. 2014;9(3):e92526.</citation>
    <PMID>24505327</PMID>
  </reference>
  <reference>
    <citation>Thayyil S, Chandrasekaran M, Taylor A, Bainbridge A, Cady EB, Chong WK, Murad S, Omar RZ, Robertson NJ. Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis. Pediatrics. 2010 Feb;125(2):e382-95. doi: 10.1542/peds.2009-1046. Epub 2010 Jan 18.</citation>
    <PMID>20083516</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

